AstraZeneca fell 9%, taking about £20 billion off its value and leaving the FTSE 100 as the only major European benchmark in the red after 1.5 hours of trading. The move came as other regional indexes stayed higher, with the London market dragged down by one stock rather than the wider tape.
The shares’ slide pushed AstraZeneca’s market value below £200 billion, a line it had still been above earlier in the session. For FTSE 100 investors, that meant the benchmark lagged even as the FTSE MIB rose 0.8%, the German DAX gained 0.4%, the IBEX added 1% and the Stoxx 600 was up 0.4%.
One trial, one stock
The trigger was the failure of the CARDIO-TTRansform trial. Michael Leuchten of Jefferies called the outcome “surprising” and said circa 2% of AstraZeneca’s net present value was at risk, equivalent to about $2.5 billion in risk-adjusted sales.
That scale matters because AstraZeneca was still the second largest company on the Footsie, with a market value of £248 billion at HSBC and £169 billion at Shell. A 9% drop in a stock of that size can move the whole index, and on this session it was enough to make London the lone major European market in the red.
Leuchten’s valuation call
Leuchten said the failure did not jeopardize the company’s 2030 $80 billion sales target, but he also warned that “Given AZN is meant to be able to design trials that are mostly water-tight, we suspect the share price reaction will go beyond the NPV impact.”
He added that the shares “may not recover until the next volatility catalyst (AVANZAR) is out of the way,” which leaves the immediate question on traders’ desks simple: whether this becomes a one-day valuation shock or a longer rerating. Citi’s earlier estimate that Wainua accounted for about 2.8% of AstraZeneca’s valuation gives a sense of how quickly pipeline assets can be priced into the stock, then repriced out.
